Affiliation:
1. N.D. Zelinsky Institute of Organic Chemistry RAS, Leninsky Prosp. 47, 119991 Moscow, Russia
Abstract
Human immunodeficiency virus (HIV) causes one of the most dangerous diseases—acquired immunodeficiency syndrome (AIDS). An estimated about 40 million people are currently living with HIV worldwide, most of whom are already on antiretroviral therapy. This makes the development of effective drugs to combat this virus very relevant. Currently, one of the dynamically developing areas of organic and medicinal chemistry is the synthesis and identification of new compounds capable of inhibiting HIV-1 integrase—one of the HIV enzymes. A significant number of studies on this topic are published annually. Many compounds inhibiting integrase incorporate pyridine core. Therefore, this review is an analysis of the literature on the methods for the synthesis of pyridine-containing HIV-1 integrase inhibitors since 2003 to the present.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference93 articles.
1. (2007). FDA approves raltegravir tablets. AIDS Patient Care STDS, 21, 889.
2. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection;Cooper;N. Engl. J. Med.,2008
3. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety;Scarci;Drugs,2020
4. Structural Biology of HIV Integrase Strand Transfer Inhibitors;Jozwik;Trends Pharmacol. Sci.,2020
5. Progress in HIV-a Integrase Inhibitros: A review of their Chemical Structure Diversity;Hajimahdi;Iran J. Pharm. Res.,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献